Conexeu Sciences Targets $2 Billion Aesthetics Gap Post-GLP-1

Traditional facial fillers are designed for precision touch-ups rather than the large-volume body contouring required by post-weight-loss patients. While fat grafting remains a surgical alternative, it often suffers from high reabsorption rates, and implants introduce foreign materials. Conexeu Sciences proposes a different approach with its thermosensitive, flowable collagen scaffold, CXU. The material is engineered to be injected through a fine needle, conforming to complex geometries before setting in situ to serve as a structural scaffold for natural tissue regeneration.

The company recently concluded its 12-month P.R.O.O.F. preclinical study, which evaluated the platform in a large-volume model. While these results have not yet undergone peer review and do not guarantee clinical success or regulatory approval, they serve as a foundation for the company’s planned 510(k) regulatory submission in early 2027. Miles Harrison, President and CEO of Conexeu, emphasized that the firm aims to establish a new category of bioregeneration, paralleling how past innovators defined the neuromodulator market. As the aesthetics industry shifts to accommodate the physical changes brought on by weight-loss drugs, Conexeu is betting that a platform capable of restoring volume at scale will capture significant market share.